Stephan Krähenbühl

Prof. Stephan Krähenbühl

Clinical Pharmacology, University Hospital Basel, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Drug Safety
Verified
Journal Article
Closed access
PDF file
AKAnita Krähenbühl-Melcher
Anita Krähenbühl-Melcher
RSRaymond Schlienger
Raymond Schlienger
MLMarkus Lampert
Markus Lampert
MHManuel Haschke
Manuel Haschke
JDJürgen Drewe
Jürgen Drewe
SKStephan Krähenbühl
Stephan Krähenbühl

29 September 2006 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
PKP. Kaufmann
P. Kaufmann
MTM. Török
M. Török
AZA. Zahno
A. Zahno
KWK. M. Waldhauser
K. M. Waldhauser
KBK. Brecht
K. Brecht
SKStephan Krähenbühl
Stephan Krähenbühl

1 January 2005 in Drug Safety
Verified
Journal Article
Closed access
PDF file
FDFabiola Delcò
Fabiola Delcò
LTLydia Tchambaz
Lydia Tchambaz
RSRaymond Schlienger
Raymond Schlienger
JDJürgen Drewe
Jürgen Drewe
SKStephan Krähenbühl
Stephan Krähenbühl

29 March 2005 in Hepatology
Verified
Journal Article
Open access
PDF file
PKPriska Kaufmann
Priska Kaufmann
MTMichael Török
Michael Török
AHAnya Hänni
Anya Hänni
PRPaul Roberts
Paul Roberts
RGRodolfo Gasser
Rodolfo Gasser
SKStephan Krähenbühl
Stephan Krähenbühl
Treatment with benzarone or benzbromarone can be associated with hepatic injury. Both drugs share structural similarities with amiodarone, a well‐known mitochondrial toxin. Therefore, we investigated the hepatotoxicity of benzarone and benzbromarone as well as the analogues benzofuran and 2‐butylbenzofuran. In isolated rat hepatocytes, amiodarone, benzarone, and benzbromarone (20 μmol/L) decreased mitochondrial membrane potential by 23%, 54% or 81%, respectively. Benzofuran and 2‐butylbenzofuran had no effect up to 100 μmol/L. In isolated rat liver mitochondria, amiodarone, benzarone, and benzbromarone, but not benzofuran, decreased state 3 oxidation and respiratory control ratios for L‐glutamate (50% decrease of respiratory control ratio at [μmol/L]: amiodarone, 12.9; benzarone, 10.8; benzbromarone, <1). Amiodarone, benzarone, and benzbromarone, but not benzofuran, also uncoupled oxidative phosphorylation. Mitochondrial β‐oxidation was decreased by 71%, 87%, and 58% with 100 μmol/L amiodarone or benzarone and 50 μmol/L benzbromarone, respectively, but was unaffected by benzofuran, whereas ketogenesis was not affected. 2‐Butylbenzofuran weakly inhibited state 3 oxidation and β‐oxidation only at 100 μmol/L. In the presence of 100 μmol/L amiodarone, benzarone or benzbromarone, reactive oxygen species production was increased, mitochondrial leakage of cytochrome c was induced in HepG2 cells, and permeability transition was induced in isolated rat liver mitochondria. At the same concentrations, amiodarone, benzarone, and benzbromarone induced apoptosis and necrosis of isolated rat hepatocytes. In conclusion, hepatotoxicity associated with amiodarone, benzarone, and benzbromarone can at least in part be explained by their mitochondrial toxicity and the subsequent induction of apoptosis and necrosis. Side chains attached to the furan moiety are necessary for rendering benzofuran hepatotoxic. (HEPATOLOGY 2005.)

16 April 2008 in Pharmacy World & Science
Verified
Journal Article
Closed access
PDF file
PVPriska Vonbach
Priska Vonbach
ADAndré Dubied
André Dubied
SKStephan Krähenbühl
Stephan Krähenbühl
JBJuerg beer
Juerg beer

1 December 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
KWKatri Maria Waldhauser
Katri Maria Waldhauser
MTMichael Török
Michael Török
HHHuy-Riem Ha
Huy-Riem Ha
UTUrs Thomet
Urs Thomet
DKDaniel Konrad
Daniel Konrad
SKStephan Krähenbühl
Stephan Krähenbühl
The aim of this work was to compare hepatocellular toxicity and pharmacological activity of amiodarone (2-n-butyl-3-[3,5 diiodo-4-diethylaminoethoxybenzoyl]-benzofuran; B2-O-Et-N-diethyl) and of eight amiodarone derivatives. Three amiodarone metabolites were studied, namely, mono-N-desethylamiodarone (B2-O-Et-NH-ethyl), di-N-desethylamiodarone (B2-O-Et-NH2), and (2-butyl-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)-methanone (B2) carrying an ethanol side chain [(2-butylbenzofuran-3-yl)-[4-(2-hydroxyethoxy)-3,5-diiodophenyl]-methanone; B2-O-Et-OH]. In addition, five amiodarone analogs were investigated, namely, N-dimethylamiodarone (B2-O-Et-N-dimethyl), N-dipropylamiodarone (B2-O-Et-N-dipropyl), B2-O-carrying an acetate side chain [[4-(2-butyl-benzofuran-3-carbonyl)-2,6-diiodophenyl]-acetic acid; B2-O-acetate], B2-O-Et carrying an propionamide side chain (B2-O-Et-propionamide), and B2-O carrying an ethyl side chain [(2-butylbenzofuran-3-yl)-(4-ethoxy-3,5-diiodophenyl)-methanone; B2-O-Et]. A concentration-dependent increase in lactate dehydrogenase leakage from HepG2 cells and isolated rat hepatocytes was observed in the presence of amiodarone and of most analogs, confirming their hepatocellular toxicity. Using freshly isolated rat liver mitochondria, amiodarone and most analogs showed a dose-dependent toxicity on the respiratory chain and on β-oxidation, significantly reducing the respiratory control ratio and oxidation of palmitate, respectively. The reactive oxygen species concentration in hepatocytes increased time-dependently, and apoptotic/necrotic cell populations were identified using flow cytometry and annexin V/propidium iodide staining. The effect of the three least toxic amiodarone analogs on the human ether-a-go-go-related gene (hERG) channel was compared with amiodarone. Amiodarone, B2-O-acetate, and B2-O-Et-N-dipropyl (each 10 μM) significantly reduced the hERG tail current amplitude, whereas 10 μM B2-O-Et displayed no detectable effect on hERG outward potassium currents. In conclusion, three amiodarone analogs (B2-O-Et-N-dipropyl, B2-O-acetate, and B2-O-Et) showed a lower hepatocellular toxicity profile than amiodarone, and two of these analogs (B2-O-Et-N-dipropyl and B2-O-acetate) retained hERG channel interaction capacity, suggesting that amiodarone analogs with class III antiarrhythmic activity and lower hepatic toxicity could be developed.